SCGC-Backed Innovative Antibody Drug Firm Gets $150M Funding From Sino Biopharm

Doris Yu
November 5, 2019 — 10:54 CST

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

Related Topics: Akeso Biopharma biotech CCB International China chinese guangdong healthcare Hong Kong Innovative Antibody Drug investment Loyal Valley Capital medicine news media OrbiMed pharmaceutical Private Equity shenzhen Shenzhen capital group Shenzhen Capital Group Company Sino Biopharmaceutical Limited venture capital

Related News:

Bahrain’s Investcorp Targets RMB2-4 Billion Buyout Fund in China

November 25, 2023 — 00:58

Chinese Generative AI Startups Secure Substantial Funding in Race to Replicate OpenAI’s Success

November 13, 2023 — 23:55

Middle Eastern Sovereign Wealth Funds Deepen Investment in China

November 10, 2023 — 23:35

Kai-Fu Lee’s AI Firm 01.AI Hits Unicorn Status with Alibaba Cloud-Led Funding

November 7, 2023 — 00:55

AI-Driven Pharmaceutical Startups Attract Soaring Investor Interest

November 5, 2023 — 03:24

Tencent Was Involved In 77 Investments Worth $11.9 Billion From 2021 To 2022 YTD; We Have It All In This One List

March 28, 2022 — 23:58

WeRide Closed Series C Round Fundraising From Alliance Ventures, China Structural Reform Fund And Pro Capital

June 23, 2021 — 20:25

Yufeng Capital: Expect To Live To 120 Years As China Realizes Digital Healthcare

April 24, 2021 — 04:25

Chinese IDM Startup InnoStar Semiconductor Secures $100M

April 8, 2021 — 01:15

Franchising and Licensing Asia (FLAsia) 2024